After Halozyme Therapeutics (HALO) confirmed it has submitted a non-binding proposal to the boards of Evotec (EVO) to acquire Evotec for EUR 11.00 per share in cash, implying a fully diluted equity value of EUR 2B, JPMorgan analyst Jessica Fye caught up with Halozyme management, who say they are interested because they see the potential to create a powerful diversified services offering by bringing in Evotec’s drug discovery, early development and biologic manufacturing capabilities. However, based on early investor feedback, the firm thinks this move was unexpected by investors and given how different Evotec is from Halozyme’s current business the firm expects it could take time for the market to think through what such a deal could mean for the company. JPMorgan maintains a Neutral rating on Halozyme shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on HALO:
- Halozyme confirms proposal to combine with Evotec for EUR 11.00 per share cash
- Evotec attracts takeover interest from Halozyme, Bloomberg says
- Halozyme interested in acquiring Evotec for $2.1B, Bloomberg says
- Halozyme price target raised to $52 from $51 at Piper Sandler
- Halozyme price target raised to $68 from $65 at H.C. Wainwright
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
